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Atrial natriuretic peptide and dopamine in established acute renal
failure in the rat. Recent studies have shown that atrial natriuretic
peptide (ANP) alone or combined with dopamine (D) markedly im-
proved renal function when given immediately after an ischemic insult.
However, the potential beneficial effect of ANP or ANP-D in the
established phase of acute renal failure (ARF) and the duration of this
effect have not been examined. In the present study atriopeptin Ill
(APIII) and D, sufficient to maintain mean arterial pressure between 100
and 110 mm Hg, or normal saline were given i.v. for four hours to
awake Munich-Wistar rats (N = 6 each group) two days after ARF
induction with intrarenal norepinephrine (NE). Renal function and
morphology were then examined two days after treatment (Day 4).
Serum creatinine (Sr) was similarly increased in both groups at the
time of APIII-D or saline infusion (Day 2). By Day 4 Se,. had decreased
to the pre-ARF induction level in APIH-D-treated rats (P < 0.005), but
continued to rise in saline-treated animals (P < 0.025). Day 4 renal
blood flow and glomerular filtration rate (GFR) were higher in APHI-D-
compared to the saline-treated group (9.13 1.14 vs. 4.41 2.25
mi/mm and 0.787 0.066 vs. 0.370 0.185 mI/mm, respectively, both
P < 0.005). Single nephron GFR was higher in APIH-D-treated rats (96
47 vs. 37 28 mI/mm, P < 0.025) primarily due to an increase in
glomerular capillary pressure (51 4 vs. 43 5 mm Hg, P < 0,02).
Urine flow rate and fractional excretion of sodium were less in
APIII-D-treated rats (P < 0.05). While comparison of percent abnormal
tubular profiles for specific kidney zones showed little difference
between the two groups, the overall sums of percent abnormal profiles
for all zones demonstrated significantly less tubular necrosis (P < 0.001)
and tubular regeneration (P < 0.025) and fewer tubular casts (P < 0.01)
in the kidneys of APIII-D-treated rats. It is concluded that APIII-D not
only increases GFR in the established phase of ARF, but the effect is
sustained. While the major effect of APHI-D may be to increase
SNOFR in at least a sufficient number of nephrons to impact on whole
kidney filtration rate, there also appears to be an effect on restoration of
tubular function and morphology.
Since the initiation of dialysis therapy four decades ago there
has been little improvement in the mortality from acute renal
failure [1]. Therapeutic attempts to alter the course of this
disease including vigorous dialysis, pharmacologic and nutri-
tional approaches have been discouraging. Recent experimental
studies, however, using atrial natriuretic peptide (ANP) have
provided some optimism that pharmacologic intervention with
this agent may attenuate the severity and enhance recovery
from acute renal failure (ARF). Schafferans et al [2], Nakamoto
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et al [3], Shaw and associates [4] and our own laboratory [5]
have shown that intravenous or intra-arterial ANP or ANP plus
dopamine (D) immediately after clamp release in renal artery
occlusion-induced ARF or immediately after cessation of infu-
sion in norepinephrine (NE)-ARF in rats will dramatically
increase glomerular filtration rate and shorten the duration of
kidney dysfunction. While these studies have been encouraging
in terms of the immediate effects of ANP on glomerular
filtration, there are substantial remaining concerns regarding
the potential clinical use of this agent in ARF. Acute renal
failure is generally not detected until hours or days after its
onset and, therefore, ANP would have to have a beneficial
effect—not only when given immediately after ARF induction—
but also at a later time in the established phase of the disease.
Secondly, the therapeutic efficacy of ANP would need to be
sustained beyond the time of infusion, since continuous, pro-
longed infusion would likely lead to unacceptable hemodynamic
complications, or possibly, agent tolerance. In addition, acute
renal failure occurs in hemodynamically unstable patients that
may not tolerate the systemic hypotensive or bradycardic
effects of prolonged ANP infusion.
In order to address these concerns, a study was designed to
examine the following questions: Will ANP favorably influence
renal function and morphology if given in the established phase
rather than immediately after induction of ARF? Is the effect on
renal function sustained beyond the period of ANP infusion? Is
D effective in maintaining systemic arterial pressure during
ANP infusion in the established (uremic) phase of ARF?
A norepinephrine (NE) induced model of post-ischemic ARF
in rats was used in which the course and pathophysiologic
profile have been studied previously [6]. Atrial natriuretic
peptide plus sufficient dopamine to maintain arterial pressure
was infused intravenously two days after ARF induction. Renal
function, determined by clearance and micropuncture measure-
ments, and morphology were assessed two days later and
compared to results obtained in control saline-infused ARF
animals.
Methods
The disease model, NE-induced ARF, has been described
previously [6, 71. Briefly, male Munich-Wistar (MW) rats
weighing 250 to 300 g underwent right nephrectomy 10 days
before disease induction. After pentobarbital anesthesia, the
left renal pedicle was exposed through a small flank incision. A
micropipette (OD 35 tm) mounted on a micromanipulator and
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attached to a motor-driven syringe containing NE was intro-
duced into the renal artery. NE was delivered at 0.6 sg/
kg. min' for 90 minutes. In separate experiments using this
technique, RBF was reduced from a preinfusion mean of 8.60
0.20 to 9.90 0.10 mI/mm for the duration of NE infusion [8].
The micropipette was removed, the surgical wound closed, and
the rats were returned to individual cages. They received water
ad libitum and a low potassium diet (ICN Pharmaceuticals,
Cleveland, Ohio, USA) for 48 hours and a standard rat chow
diet (Wayne Feed, Longmont, Colorado, USA) thereafter.
Venous blood samples were obtained prior to and on Days 2
and 4 after ARF induction for measurement of serum Na and
creatinine (Scr).
On Day 2 post-ARF induction, right femoral artery and vein
catheters were positioned under light methoxyflurane anesthe-
sia. The rats were allowed to awaken and placed in a restraining
cage. Arterial pressure was monitored with an electronic trans-
ducer (P23DB; Statham Instruments, Oxnard, California, USA)
and a direct-writing recorder (7702B; Hewlett-Packard Co.,
Palo Alto, California, USA). An infusion of atriopeptin III
(APIII) (Bachem, Inc., Torrance, California, USA), 0.25 p.g/
kg. min, plus sufficient dopamine (Lypho Med. Inc., Mel-
rose Park, Illinois, USA) to maintain mean arterial pressure
between 100 and 110 mm Hg was given intravenously over four
hours to six rats. The hourly infusion volume was 1.0 to 1.3 ml.
The rate of D delivery required to maintain arterial pressure
varied from 0.8 to 9.0 .tg/kg. min. In a separate group of six
rats 0.9 percent saline intravenously for four hours was substi-
tuted for APIII and D. The rate of delivery was adjusted to
match volume delivered to the APIII-D treated rats. Following
infusions, rats were again lightly anesthetized with methoxyflu-
rane for catheter removal and vascular repair and returned to
individual cages.
Two days later (Day 4 post-ARF induction) the rats were
prepared for clearance and micropuncture experiments as pre-
viously described for this laboratory [9]. Following pentobar-
bital anesthesia (60 mg/kg i.p.), a tracheostomy was performed
and catheters were placed in the left jugular and left femoral
veins and femoral artery. The left kidney was exposed through
a flank incision, dissected free from surrounding tissue and
placed in a lucite cup. The femoral vein catheter was advanced
into the left renal vein by a technique described previously for
this laboratory [10]. The left ureter was catheterized for urine
collection. Arterial blood pressure was continuously monitored
as described above. An intravenous infusion of 0.9 per cent
saline was given at 1.5 mI/hr to which inulin and para-amino-
hippurate (PAH) were added to give plasma levels of 50 to 100
and 2 to 4 mg/dl, respectively. Tail vein and renal venous blood
samples were obtained between 50-.d timed urine collections
for measurement of Na, inulin and PAH. Thereafter, at least
five two-minute collections of proximal tubular fluid were made
with 8 tm outside diameter oil-filled pipettes at the pressure
existing in the tubule. The method of maintaining tubule pres-
sure was described previously [6]. In order not to introduce
examiner bias, individual nephrons to be studied were chosen
by accepting the tubule which lay beneath a cross-hair placed in
the ocular of the microscope. Subsequent nephrons were Se-
lected in the same manner after shifting blindly to a new
microscopic field. With a servo-null pressure monitoring device
(Instruments for Physiology and Medicine, San Diego, Califor-
nia, USA), an electronic transducer (Statham model P23Db,
Gould, Inc., Oxnard, CA), hydraulic pressures were measured
in glomerular capillaries (PGC), efferent star vessels (Ps) and
proximal tubules (PT). At least three measurements were made
in each animal. Two to five samples of efferent arteriolar blood
were collected for protein concentration with 14 m outside
diameter oil-filled pipettes that had been coated with a 1:10 (vol)
solution of Dow-Corning 1107 fluid (Dow Corning Corp., Mid-
land, Michigan, USA) and trichioroethylene. Tail vein blood
samples (10 p.1) were taken at the beginning and end of the series
of efferent arteriolar blood collections of inulin and protein
concentration. At the conclusion of the micropuncture mea-
surements, tail and renal vein blood and timed urine collection
were repeated for Nat, inulin and PAH. If the pre- and
post-micropuncture values of urinary sodium excretion rate
(UNAV), inulin clearance (C1), and paraaminohippurate clear-
ance (CPAH) (adjusted for extraction fraction) differed more
than 10%, the experiment was discarded.
The kidneys were removed prior to animal sacrifice with an
overdose of pentobarbital. Three coronal sections of the kid-
neys were fixed in neutral buffered formalin, embedded in
paraffin, sectioned at 3 p., and stained with hematoxylin and
eosin, PAS-hemotoxylin and Masson's trichrome stains. Sec-
tions were examined blindly by one of us (WSH) for the nature
and severity of tubulointerstitial and vascular injury. The cor-
tex, inner and outer medullary stripes, and the inner medulla of
each coronal section were each mapped into adjacent low
power (4 x 10 x) microscopic fields. Unselected centrally-
located higher power fields (20 x 10 x) were chosen from low
power fields for analysis of tubular changes. From 8 to 14 fields
from the cortex, 6 to 11 fields from the outer stripe, 5 to 7 fields
from the inner stripe and 1 to 3 fields from the inner medulla
were examined from each animal. The number of fields exam-
ined varied by the number of fields available which depended on
variation in area of the individual cross section. Using an ocular
grid, the total number of tubular profiles, and the number of
profiles with dilatation, necrosis (either necrosis of the lining
epithelium or necrotic debris in the lumen), regeneration or
casts was recorded. Mitoses were included in the determination
of regeneration. The outer medulla of each coronal section was
then surveyed and the bundles of vasa recta enumerated. From
41 to 133 bundles from each animal were examined. Each
bundle was scored as normal, congested with erythrocytes, or
containing increased numbers of nucleated cells. PAS-stained
sections were surveyed and arterial profiles with myonecrosis
were enumerated. Interstitial changes (fibrosis and inflamma-
tion) were assessed for each section on a semiquantitative (0 to
4+) scale.
Analytic techniques
Plasma and urine inulin and PAH and serum creatinine were
measured with a Technicon Autoanalyzer (Technicon Instru-
ments Corp., Tarrytown, New York, USA). Tubular fluid inulin
was estimated by the micromethod of Vurek and Pegram [11] as
modified for this laboratory [12]. Plasma and urine sodium
concentrations were determined by flame photometry.
The phthalaldehyde fluorometric microprotein method as
adapted for this laboratory [13] was used to measure systemic
and efferent arteriolar protein concentrations. Plasma colloid
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osmotic pressure was determined from the Landis and Pappen-
heimer formula [141:
ii (mm Hg) 2.1C + 0.16C2 + 0.001C3
where C represents total protein concentration (in grams per
deciliter).
Whole kidney glomerular filtration rate (GFR) was estimated
from C. and RBF was derived from CPAH adjusted for kidney
extraction fraction and hematocrit [151.
Single nephron glomerular filtration rate (SNGFR) was cal-
culated from the formula:
SNGFR = CR x TF/P1
where CR represents tubular fluid collection rate and TF/P1 the
tubular fluid to plasma inulin ratio.
Proximal tubular absolute reabsorption (J) was estimated
from the expression:
= SNGFR — CR
Proximal tubular fractional reabsorption (FR) was calculated
FR Jv/SNGFR
as:
Single nephron filtration fraction (SNFF) was calculated from
the equation:
SNFF = I — (CA/CE)
where CA and CE denote afferent and efferent arteriolar protein
concentrations, respectively.
Glomerular plasma flow rate was
QA SNGFRJSNFF
where QA refers to glomerular plasma flow rate.
Blood flow rate per single afferent arteriole or glomerulus was
calculated as
GBF = QAI(l — HctA)
where the hematocrit or afferent arteriolar blood was taken to
be equal to the femoral arterial hematocrit.
Efferent arteriolar blood flow rate was determined as:
EABF = GBF — SNGFR
Resistance per single afferent arteriole was derived from the
formula:
RA = [(MAP — Poc)/GBF1 X (7.962 X lOb)
where the factor 7.962 x 1010 is used to give resistance in units
of dynes/sec/cm5 when MAP and GC are expressed in millilters
of mercury and GBF in nanoliters per minute.
Resistance per single efferent arteriole was derived from the
formula:
RE [(Poc — PE)/EABF] X 7.962 X 1O'
where P is the pressure recorded in the efferent "star" vessel.
Mean glomerular transcapillary pressure difference was cal-
culated as:
= 'OC
I
2
Time, days
Fig. 1. Serum creafinine measurement prior to ARF induction (Day 0),
just prior to saline or APIII-D treatment two days later (Day 2) and two
days after respective treatments on Day 4. Symbols are (O----O) saline;(•----•) APIII-D. Serum creatinine was similarly elevated in the two
groups on Day 2 compared to Day 0 (P < 0.05), declined significantly
thereafter on Day 4 (P < 0.005) in the APIII-D-treated rats, but
continued to increase over the same time period in the saline-treated
animals (P < 0.025).
The ultrafiltration coefficient (Kf) was determined by the
block iteration described by Blantz [16].
Data are expressed as means SD. Intergroup parameter
comparisons were made by unpaired t-test. Overall time-related
comparisons within a group were made by analysis of variance
for multiple measurements and individual comparisons were by
Scheffe's method [171. Because of the nature of fractional
sodium excretion (FENa) data, that is, a normal mean value
approaching 0 with no physiological possibility of symmetrical
distribution of data about the mean, a non-parametric
(Wilcoxon rank sum) test was used to compare this measure-
ment between the two groups.
Results
Serum creatinine profiles for the four days of study are shown
in Figure 1. Pre-induction Se,. were 0.67 0.07 and 0.65 0.08
mg/dl, respectively, in saline and APIII-D-treated rats, (N = 6
each group, P = NS). By Day 2 S.had increased significantly
to 1.65 0.60 mg/dl in the saline-treated group (P < 0.05) and
2.02 0.99 mg/dl in the APIII-D-treated animals (P < 0.05).
Following respective treatment infusions, mean Sr continued
to increase to 2.78 2.11 mg/dl on Day 4 in saline-infused rats
(P < 0.025 compared to Day 2), but fell to 1.21 0.81 mg/dl in
APIII-D-treated animals (P <0.005 compared to Day 2). The
latter value was similar to that prior to ARF induction on Day
0. Whole kidney clearance data obtained on Day 4 are given in
Table 1. Body weights declined with ARF. However, they were
similar in the two groups on Day 4 as shown in Table 1 as they
were on Day 0 (328 4 in APIII-D-treated vs. 328 6 g in
saline-treated rats) and Day 2 (311 7 in APIII-D-treated vs.
309 10 g in saline-treated rats). Hematocrits and mean arterial
pressures also were similar in the two groups on Day 4. While
kidney weights were less in APIII-D-treated rats (P < 0.01),
RBF was more than twice that in saline-treated animals (P <
0.005). Glomerular filtration rate also was twofold higher in
C
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Table 1. Whole kidney function parameters
Body wt Kidney wt Hct
vol %
MAP
mm Hg
RBF GFR
mi/mm
v
pi/min
UNOV
pEqimin FEN0 0Group g
1. ARF- 303 1.85 48 114 4.41 0.370 11 3.62 1.32
saline (6) 26 0.13 3 14 2.25 0.185 1 2.21 1.53
2. ARF- 295 1.47 49 103 9.13 0.787 7 2.26 0.21
AP III-D (6) 7 0.23 2 6 1.14 0.066 2 0.52 0.03
P 1. vs 2. NS <0.01 NS NS <0.005 <0.001 <0.01 NS <0.050
Values are means SD. Numbers in parentheses are numbers of rats. Abbreviations are: Hct, arterial hematocrit; MAP, mean arterial pressure;
RBF, renal blood flow; GFR, whole kidney glomerular filtration rate; V. urine flow rate; UNaV, urinary sodium excretion rate; FENa, fractional
excretion of sodium.
0 Wilcoxon rank sum test used for comparison; see Methods for explanation.
APIII-D-infused kidneys (P < 0.001). Whole kidney filtration
fractions were low but similar in both groups (0.16 0.05 in
saline-infused and 0.17 0.04 in APIII-D-treated animals).
Urinary sodium excretion was similar, but urine flow rate and
FENa were both lower in APIII-D-infused kidneys (P < 0.01
and P < 0.05, respectively). Fractional excretions of sodium are
shown in Figure 2.
Micropuncture data on Day 4 are shown in Table 2. Despite
maintaining existing tubular pressure during collections, there
was marked variation in SNGFR randomly measured from late
proximal tubules on the surface of each kidney in both groups,
as illustrated in Figure 3. Nonetheless, the mean SNGFR of 96
47 nI/mm in the APIII-D-treated rats was significantly greater
than the 37 28 nI/mm calculated for saline-treated animals (P
< 0.025). Of the determinants of SNGFR only P was consis-
tently and statistically higher in the kidneys of APIII-D-treated
rats (35 5 vs. 25 3 mm Hg in the kidneys of saline-treated
animals, P < 0.05). Proximal tubular pressures were similar in
the two groups. The differences in P were the result of higher
P values in the APIII-D-treated groups (52 4 vs. 43 5 mm
Hg in the saline-treated group, P <0.02). Calculated values of
QA and K were sufficiently variable that no statistical differ-
ences in mean values between the two groups were detected.
Nonetheless, in sampled nephrons SNFF was twofold higher in
the kidneys of APIII-D-treated rats, a finding not reflected in
whole kidney filtration fraction. RA and RE in both ARF groups
were low compared to those in normal kidneys [18], however,
the respective values were not statistically different between
APIII-D and saline-treated animals. Mean efferent star vessel
hydraulic pressure (PE) was higher in kidneys of APIII-D-
treated rats.
Absolute volume reabsorption by the proximal tubule was
substantially greater in the APIII-D-treated group (P < 0.02).
However, fractional volume reabsorption by the proximal tu-
bule was not significantly different.
Morphologic assessment of tubular pathology on Day 4 is
shown in Table 3. Injury, as determined by most parameters,
was most severe in the cortex and outer stripe. However,
tubular casts were more frequent in the inner stripe and inner
medulla. When comparisons were made between percents of
tubules with abnormal profiles in separate anatomic kidney
zones, there were found to be significantly more casts in
cortical tubules (P < 0.05) and increased evidence of regener-
ating tubules in the inner medulla (P < 0.05) in the saline-
treated group. Despite the significant differences, the percents
of tubules showing cortical casts and regeneration in the inner
medulla were infrequent in both groups. There were no other
significant differences in the percents of tubules with specific
pathologic factors when comparisons were made between re-
spective kidney zones in the APIII-D- and saline-treated
groups. However, if data were analyzed by summing the
percents of abnormal tubular profiles for all zones (cortex, outer
and inner medullary stripes and inner medulla) of the kidneys in
both groups, statistical differences were identified. These
"overall" differences were found in the summed percent of
tubules showing necrosis (P < 0.001), regeneration (P <0.025)
and casts (P < 0.01). With each pathologic factor, the percents
were less in the APIII-D-treated kidneys. There were no
differences in the "overall" percents of tubules showing dila-
tion.
No differences between the APIII-D- and saline-treated
groups were revealed by analysis of the vasa recta. In the
APIII-D-treated kidneys 34.6 15.5% of the vasa recta bundles
were congested and 7.0 6.6% contained increased numbers of
nucleated cells. In the saline-treated group these same percent-
ages were 37.2 14.3% and 9.7 6.1%, respectively. In both
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Fig. 2. Fractional excretion of sodium data for individual saline- and
AP!I!-D-treated rats on Day 4. The values for the two groups were
significantly different by Wiicoxon rank sum test (P < 0.05).
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Table 2. Individual nephron measurements of glomerular and tubular dynamics
Treatment group
SNGFR
nI/mm
GC i E
SNFF
A
mm Hg
E
mm Hg
I.
2.
P
ARF-saline (6)
ARF-AP III-D (6)
1. vs 2.
37 2896 47
<0.025
43 551 4
<0.02
18 4
16 5
NS
9 317 4
<0.005
24 4
35 7
<0.005
0.14 0.06
0.27 0.06
<0.05
14 1
15 1
NS
17 I
25 5
<0.02
Values are means SD. Numbers in parentheses are numbers of rats. Abbreviations are: SNGFR, single nephron glomerular filtration rate; POC,
glomerular capillary hydraulic pressure; T, proximal tubular pressure; P, efferent star vessels; P, net hydraulic ultrafiltration; SNFF, single
nephron filtration fraction; IrA, afferent arteriole colloid pressure; 11E. efferent arteriole; QA' glomerular plasma flow; RA, resistance per single
afferent arteriole; RE, resistance per single efferent arteriole; K, ultrafiltration coefficient; FR, proximal tubular fractional reabsorption; and iv,
proximal tubule volume reabsorption.
Table 2. Continued
QA
ni/mm
RA RE Kf
ni/sec/mm Hg
Jv
ni/mm FR %X 1O'°dynes/sec/cm5
263 176 1.15 1.73 0.59 0.90 0.1096 0.6194 18 14 43 22382 215 0.55 1.01 0.42 0.76 0.1146 0.6061 67 37 65 12
NS NS NS NS <0.02 NS
8
0
I
10_I
Saline APIII-D
Fig. 3. Individual single nephron glomerular filtration rate measure-
ments for saline- and APIII-D-treated rats on Day 4. The mean values
were different at P < 0.025.
groups, the nucleated cells were a mixture of mononuclear cells
and neutrophils. Myonecrosis of arteries was restricted to
extrarenal vessels and rare arcuate and interlobular arteries. No
differences in arterial injury in the two groups of animals were
identified. Similarily, no differences in the degree or nature of
interstitial fibrosis were detected. Mean scores of a semi-
quantitative, 0 to 4+, grading system were 1.7 0.8 for each
group.
To summarize the morphologic findings, differences between
the APIII-D- and saline-treated kidneys in percents of tubules
with specific abnormalities within individual zones were limited
to marginal differences in cortical casts and inner medulla
regeneration. However, when the differences in percents of
abnormalities were amplified by summing the percents for all
zones, evidence of tubular necrosis, regeneration and casts was
less in the APIII-D-treated rats.
Discussion
The results of these experiments indicate that ANP-D have a
positive and sustained impact on renal function when adminis-
tered in the established phase of an ischemic model of ARF. In
addition, D effectively counteracted the hypotensive effect of
systemically administered ANP in a setting of acute uremia.
The significance of these findings are more readily appreciated
when two related points regarding ischemic ARF are consid-
ered. Previous experimental investigations [2—4], including that
from our laboratory [5], have shown a promising potential for
ANP or ANP-D to reverse the deleterious effects of ischemia on
renal function. However, in all of these studies ANP or ANP-D
was infused immediately after ischemia induction. A number of
pathophysiologic features of ARF present in the established
phase likely had not evolved at the time of treatment interven-
tion. These would include extensive tubular cast formation and
marked elevation of tubular pressures [6], changes in renal
hemodynamics subsequent to tubular obstruction [19] and a
uremic cellular environment. Thus, while ANP or ANP-D
effects have been assessed in models of abrupt ischemic injury,
they had not been tested in established ARF. This distinction
has more than pathophysiologic relevance. Recognition of
ischemic ARF in the clinical setting generally requires hours
and frequently days. Therefore, if pharmacologic intervention
is to have practical benefit, its effects must be determined at
some point remote from the initial ischemic event.
Evidence that a transient infusion of ANP-D had a prolonged
residual effect on filtration function of the ARF kidney included
the observed distinct improvement in and a C1, twice that in
the saline-treated rats on Day 4. While demonstrating an effect
of ANP-D on glomerular filtration was the primary goal of these
experiments, it was of some concern that abruptly improving
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Table 3. Abnormal tubular histopathologic profiles on Day 4
Outer medullary Inner medullary
Pathologic Cortex % stripe % stripe % Inner medulla % Overalla %
factor APHL-D Saline AP-III-D Saline APIII-D Saline APIII-D Saline APIII-D Saline
Dilatation 17.3 21.1
13.8 10.1
14.5 15.3
7.4 6.6
3.1 3.7
3.1 2.6
1.2 0.2
2.4 0.3
36.1 39.6
6.6 4.9
P value NS NS NS NS NS
Necrosis 11.6 24.8
14.8 13.7
20.9 34.2
18.9 18.1
4.6 8.6
4.1 8.3
0.0 8.8
0.0 20.2
37.1 76.4
9.4 15.0
P value NS NS NS NS <0.001
Regeneration 18.6 26.6
18.2 14.1
34.2 42.3
27.2 17.9
10.3 10.1
8.4 8.0
0.0 0.5
0.0 0.6
63.1 79.5
13.5 10.2
P value NS NS NS <0.05 <0.025
Casts 1.6 5.1
1.8 2.8
3.2 3.6
3.1 3.1
20.2 25.0
16.4 17.5
10.2 18.5
10.1 22.5
35.1 52.2
7.9 11.5
P value <0.05 NS NS NS <0.01
Data are based on examination of three sections of each of the six kidneys in the AP-III-D- and saline-treated rats, and represent the mean
percents of tubular profiles per kidney demonstrating the selected pathologic factors.aThe "overall" category is the mean for the six kidneys in each group of sums of percents of tubular profiles for all separate zones demonstrating
the specific pathologic factor.
glomerular filtration into dysfunctional tubules could lead to a
marked diuresis, hypovolemia, recurrent ischemic injury and
worsening azotemia [20, 211. This sequence of events was not
observed. Body weights did not decline in the ANP-D-treated
group and urine flow rate and FENa were slightly lower on Day
4. These observations suggest that early restoration of GFR in
this setting did not have deleterious systemic or renal paren-
chymal effects. Morphologic evidence also did not indicate that
enhancing tubular workload by increasing GFR had a negative
effect on tubular healing. Atrial natriuretic peptide has been
shown to directly inhibit sodium and water reabsorption, par-
ticularly in distal nephron segments [22]. Thus, it is possible
that a transient ANP-induced reduction in tubular reabsorptive
work permitted greater expenditure of available energy in
re-establishing cellular integrity. In addition to concerns about
increased filtered load, abrupt improvement in RBF was also
considered a potential mechanism for aggravating tubular and
vascular injury. There is a body of evidence suggesting that
post-ischemic reperfusion causes cellular injury via toxic 02
metabolites [23, 241. Such injury was not evident. The latent
increase in RBF (>2 days post-ischemic insult) may have had a
positive, rather than negative, effect on tubular healing via
improved 02 and substrate delivery. It is of interest to note that
kidney weights on Day 4 were less in APIII-D-treated rats
despite improved RBF suggesting that tubular volume and
interstitial edema had been reduced. In addition, "overall"
tubular morphology (as estimated from the sums of percents of
tubules with necrosis, regenerative changes and casts in sepa-
rate kidney zones) was improved in ANP-D-treated rats.
While it is clear from the clearance measurements and 5Cr
proffles that ANP-D improved overall kidney function, it is less
clear what the precise effects of this pharmalogic combination
were on the intrarenal pathophysiologic processes maintaining
ARF 2 days after ischemia induction. It was not technically
feasible to subject the ARF rats in the present study to multiple
micropuncture experiments. However, a number of inferences
can be drawn from previous serial measurements of glomerular
and tubular dynamics in a study using an identical NE-induced
ARF model [6] and from the micropuncture data on Day 4 in the
present study. At two days after initiating ischemic insult in the
previous study proximal tubular pressures varied widely from 5
to 45 mm Hg. Single nephron glomerular filtration rates, how-
ever, were relatively uniform so long as the existing tubular
pressures were maintained during tubular fluid collections.
Values of SNGFR with pressure controlled collections varied
from 0 to 10 nI/mm in the majority of nephrons which correlated
roughly with whole kidney GFR measurements. When tubular
fluid collections were repeated from these same tubular sites at
reduced tubular pressures, SNGFR increased dramatically in
nephrons with high initial tubular pressures but changed little in
nephrons with low initial tubular pressures. From these data it
was deduced that the pathogenetic mechanism maintaining
reduced GFR two days after NE induction of ARF was a
heterogeneous mixture of two basic processes, tubular obstruc-
tion and pre-glomerular arterial (or arteriolar) vasoconstriction.
The distribution of the tubular pressure data suggested that both
mechanisms were contributing in approximately equal propor-
tions to overall GFR reduction. If it is assumed that the two-day
post-ischemia findings in this previous study [6] are repre-
sentative of the pathophysiologic factors present in the current
study at the time of APIII-D infusion, then a reasonable
speculation can be made regarding the specific effects of
APIII-D when comparisons are made with the micropuncture
observations on Day 4. At the latter time proximal tubular
pressure were only slightly elevated and relatively consistent
(16 5 mm Hg). On the other hand, SNGFR values were highly
variable despite maintenance of existing pressures during tubu-
lar fluid collections (Fig. 2). Some SNGFR values were excep-
tionally elevated to as much as three- to fourfold higher than
mean values even for uninephrectomized rats [25]. Glomerular
capillary hydraulic pressures measured from available surface
glomeruli were elevated in APIII-D-treated rats compared to
both the saline-treated group and mean values reported in
normal MW rat kidneys [26]. What the comparative data
suggest are that hydraulic pressures in glomeruli of obstructed
nephrons were elevated sufficiently by APIII-D to dislodge
obstructing tubular cast restoring normal or even elevated
SNGFR levels. The minimally elevated and uniform tubular
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pressures on Day 4 would support the contention that casts
were dislodged as would the morphology showing cortical and
"overall" reduction in the frequency of tubular casts. In
addition, despite its observation in a dissimilar ARF model,
marked elevations in P0 (65 4 mm Hg) and visual observa-
tion of movement of casts through tubules have been seen
during APIII-D infusion in a previous study [5]. While elevation
of P and removal of casts from obstructed nephrons may
explain the normal to elevated SNGFR values, the relatively
low SNGFR measurements in some nephrons despite normal or
nearly normal tubular pressures suggest that APIII-D only
partially relaxed constricted preglomerular arterial vessels.
Against this possibility were the consistently normal to high
measurements of GC However, this may have represented an
unintended sampling error, since there are a limited number of
surface glomeruli and those with reduced capillary pressures
and flows are difficult to identify. Failure to dilate constricted
preglomerular arterial vessels could be due to pre-existing
effects of locally generated endothelin in areas of more severe
ischemic vascular injury [27].
Despite the fact that SNGFR determinations varied widely
two days after APIII-D infusion, there was clearly an overall
increase in randomly measured values compared to those
obtained in the saline-treated rats. It is interesting to note that
tubular pressures also approached normal in the saline-treated
group on Day 4 when P0 values were in a normal range,
indicating that tubular obstruction was no longer a major
detectable contributing factor to GFR reduction. The relatively
small percent of tubular casts—particularly in the cortex and
outer stripe—in both animal groups would also tend to support
a lesser role for tubular obstruction on Day 4. This observation
is consistent with the findings in our previous study in which
elevated tubular pressures tended to normalize between the
third and seventh day after NE-ARF induction, with significant
improvement in single nephron and whole kidney glomerular
filtration rates. When the data from the present experiments are
considered together with the sequentially obtained data of our
previous study [6], the overall effect of APIII-D appeared to be
an increase in pre-, intra- and post-glomerular hydraulic pres-
sure profiles that accelerated the spontaneous recovery pro-
cess. Improved post-glomerular perfusion, while not necessar-
ily improving function, did not appear to damage tubules.
The pharmacologic action of ANP on glomerular hemody-
namics has been addressed in normal and post-ischemic kid-
neys. ANP has been shown to increase GC by reducing RA and
increasing RE [28]. Recent studies which have directly mea-
sured ANP effects on isolated AA and EA have confirmed
vasorelaxation in the former and vasoconstriction in the latter
[291. In a previous study assessing the effects of combined
infusions of ANP and D, the results suggested that the latter
may have attenuated the increase in RE observed with ANP
alone [5]. The attenuating effect of D on ANP-induced RE
increase may have contributed not only to an overall increase in
RBF, but more specifically to increased perfusion of the post-
glomerular capillary network.
In assessing the results of the present study it is necessary to
point out that some of the data must be interpreted with
caution. While directly obtained clearance and micropuncture
measurements are sound, data that were calculated using gb-
merular or efferent arteriolar hydraulic pressure or efferent
arteriolar colloid osmotic pressure including SNFF, QA,RA, RE
and K1 are gross estimates. It is acknowledged that these
calculated values have a lesser degree of reliability than directly
measured parameters in micropuncture experiments because of
the limited sample size of GC, E and E and the fact that they
are rarely obtained from nephrons in which SNGFR is mea-
sured. However, the reliability of these calculated values is
more questionable in the present study because of the wide
variation in SNGFR values and the likelihood that the limited
measurements of GC, E and ITE did not reflect the heteroge-
nous conditions among individual nephrons. Nonetheless, it
was elected to report these calculated data as an overall
estimate of changes in gbomerular dynamics, but only with the
stated reservations outlined above.
A final issue requiring explanation is the failure to perform
separate experiments with APIII or D alone. These were not
carried out for a number of reasons. First, APIII alone on Day
2 in NE-ARF rats in doses previously shown by our laboratory
[5] and Nakamoto et a! [3] to be efficacious in immediate
post-ischemic infusion models produced profound hypotension
and occasional death in preliminary studies, and lower doses
that did not alter arterial pressure did not improve renal
function. Secondly, the doses of D used to support arterial
pressure during API!! infusion varied over a wide range. When
initial trials of the high doses of D used during API!! infusion
were given alone, there was marked systemic hypertension and
renal vasoconstriction. When lower doses of D were infused
that did not elevate systemic arterial pressure or reduce RBF,
there was no effect on subsequent renal function as was also
shown previously in a study from our laboratory [5]. Finally,
insofar as these experiments have potential clinical relevance, it
is most unlikely that ANP alone can be administered systemi-
cally to ARF patients without significant negative hemody-
namic consequences as was suggested by the recent report of
Gotz et a! [291. In that study ANP infusion rate was limited to
only 2.5 g/min in order to avoid hypotension. At this dose they
showed no positive effects on renal function. Thus, in the
present study the whole kidney and single nephron effects of a
combination of pharmabogic agents likely to have a potential
clinical application were examined.
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